EditorialEditorial

Clin Osteol 2004; 9(1): 3

Body weight and boneArticles

J. Blahos

Clin Osteol 2004; 9(1): 4-5

The relationship between obesity and bone tissue is being studied concerning the influence of the amount of fat tissue and its changes on bone mine­ ral density (BMD), on markers ofbone turnover and on the risk of osteoporotic fractures. The relationship between body weight and bone mass is most decisively influenced by mechanic and humoral factors. The body weight has a mechanical effect on osteocyte mechanosensors. Other involved im­ portant factors are: embryonal relationship between osteoblasts and adipocytes, the genetic relationship between fat and bone tissue, the influence on vascularisation and the cytokine network. The humoral factors include...

Bisphosphonates in the management of metabolic skeletal disorders in adultsArticles

V. Vyskočil

Clin Osteol 2004; 9(1): 6-10

Bisphosphonates play a leading role in the treatment of several metabolic bone diseases. Bisphosphonates are currently being used to succesfully treat postmenopausal, senile, male and glucocorticoid-induced osteoporosis, Paget's disease of bone, osteolytic bone disease of malignancy and post-trans­ plant bone disease. Bisphosphonates are considered as prom an overview on current therapeutic use of bisphosphonates.

The possibilities of using biphosphonates in the treatment of children and adolescentsArticles

S. Kutilek, M. Bayer, V. Vyskočil

Clin Osteol 2004; 9(1): 11-15

Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption. Bisphosphonates have been used in adults with postmeno­ pausal and secondary osteoporosis, hypercalcemia of malignancy, immobilization-induced hypercalcaemia, bone metastases, heterotopic ossifications, post-transplant bone disease and Paget's disease. Although not approved by regulatory authorities for use in children, bisphosphonates have been su­ ccessfully used to treat children with osteogenesis imperfecta, idiopathic juvenile osteoporosis, secondary osteoporosis, fibrous dysplasia of bone, hy­ percalcemia. Current limitations in children are due to lack of...

A critical analysis of the WHI study from the point of view of prevention and management of osteoporosisArticles

J. Jeníček

Clin Osteol 2004; 9(1): 16-17

The WHI study was done with a population that greatly differs from the current population ofmenopausal women. To apply its results in practice israther difficult. The mean age of the women was 63 years - and even the oldest women were given the same dose of conjugated estrogens (0.625 mg). For years now we have been administering to older women lower estrogen doses and, moreover, we have at our disposal preparations with modern ges­ tagens (dydrogesterone, dienogest) or tibolone.

Profile of patients presenting with postmenopausal osteoporosis treated with raloxifeneArticles

J. Rosa, P. Vaňuga, M. Noskovič, A. Ritomský

Clin Osteol 2004; 9(1): 18-21

Appropriate patient's compliance is a pre-requisite for effective long-term treatment of osteoporosis. Compliance data from randomized clinical trials generally do not provide reliable compliance-related information in clinical practice. CORAL (COmpliance with RALoxifene Therapy) is a local Slo­ vak prospective multicentric observational study. Primary goal is to evaluate compliance with raloxifene treatment in clinical practice conditions. Se­ condary goals include quality of life, safety and proportion of patients at increased cardiovascular risk assessments. The 18-months observation inclu­ des 1 517 patients by study start with diagnosed postmenopausal...

Development of International Nomenclature of constitutional disorders of bone up to 2001 - application to the clinical practiceArticles

I. Marík, M. Kuklík, A. Maríková

Clin Osteol 2004; 9(1): 22-26

International Nomenclature of Constitutional Disorders of Bone was for the first time performed by committee of experts for nomenclature of intrin­ sic disorders of bone of the European Society of Pediatric Radiology in Paris, 1969 (published in 1972). In 1977 was done the first revision and in 1983 the second revision of International Nomenclature of Constitutional Diseases of Bone (again in Paris). The third revision - 4th version - of Internatio­ nal Classification ofOsteochondrodysplasias (OCHD) was perfomed by international working group on bone dysplasias in Bad Honnef, 1991. This clas­ sification was exclusively based on radiodiagnostic criteria,...

Hip protectors - new developmentsInformations

V. Šmajstrla, L. Borotík, J. Zvolský

Clin Osteol 2004; 9(1): 27-30

Hip fractures are increasing epidemically and become great health-care and economic problem of developed countries. Hip-protectors (hip-savers, hip-pads) are widely used to prevent osteoporotic hip-fractures in risk population. They consist of pants with special padding in big trochanter area. These pants underwear under common clothes. They are produced in lot of modifications and sizes. Their effectiveness was proved in laboratory tests (reduction of impact energy under the treshold of fracture 3kN) and many clinical trials (approx. one-half reduction of hip fractures). Low accep­ tance and compliance were however recorded in majority of trials....

Abstracts from abroadLiterature

Clin Osteol 2004; 9(1): 31

Congress announcementsInformations

Clin Osteol 2004; 9(1): 32

Osteological bulletin, volume 8 - Index of topics (2003)Informations

Clin Osteol 2004; 9(1): 33

Autors' IndexInformations

Clin Osteol 2004; 9(1): 34

INSTRUCTIONS TO AUTHORSInformations

Clin Osteol 2004; 9(1): 35-36